Related Experiment Video
Updated: Jul 5, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Potential therapeutic targets for colorectal cancer and its subsites: evidence from the proteome-wide Mendelian
Jinyi Li1, Yuanda Liu2, Chang Liu2
1School of Traditional Chinese Medicine, Changchun University of Traditional Chinese Medicine, Changchun, China.
Background:
Colorectal cancer (CRC) is the most common malignant tumor of the digestive tract worldwide, however, the potential targets for CRC and its subsites (colon cancer & rectum cancer) are less known. The aim of this study is to explore potential therapeutic targets for CRC.
Methods:
A proteome-wide genome-wide association studies (GWAS) in 35,559 Icelanders with 4,907 plasma proteins was used as instrumental variables (P value <5×10-8). The discovery stage consisted of the CRC GWAS with the largest sample size (CRC: 14,886 cases; colon: 3,793 cases; rectum: 2,091 cases). The significant proteins were further validated in the FinnGen study with 5,458 CRC cases (3,292 colon + 2,017 rectum). We identified relevant protein loci in CRC by two sample Mendelian randomization (MR) [false discovery rate (FDR) <0.05], colocalization analysis was used to further determine the relevance between CRC and plasma proteins, enrichment analysis and drug prediction were used to predict protein function.
Results:
A total of 31 proteins were found to be in robust causal associations with CRC and the proteins' effects displayed anatomic site-specificity in MR analysis. The subsequent colocalization analysis pinpointed that CHDRL2 had a shared region with CRC and its two subsites, suggesting the importance of targeting it. Besides, IGF2R and ENPEP displayed anatomic site-specificity to colon cancer while ASRGL1 was strongly correlated only with the risk of rectal cancer. Enrichment analysis revealed functions of these proteins in CRC, and DrugBank showed their target drug.
Conclusions:
In summary, our study has identified a common protein, CHDRL2, as the drug targets for CRC and its subsites. Besides, IGF2R and ENPEP displayed anatomic site-specificity to colon cancer while ASRGL1 was strongly correlated only with the risk of rectal cancer.
Insights
This study identifies CHDRL2 as a potential therapeutic target for colorectal cancer (CRC) and its subsites. Specific proteins like IGF2R and ENPEP are linked to colon cancer, while ASRGL1 is associated with rectal cancer.
Area of Science:
- Genetics and Genomics
- Oncology
- Proteomics
Background:
- Colorectal cancer (CRC) is a leading global malignancy.
- Understanding specific molecular targets for CRC and its subsites (colon and rectal cancer) remains crucial for effective treatment.
- This study aimed to identify novel therapeutic targets for CRC.
Purpose of the Study:
- To explore potential therapeutic targets for colorectal cancer (CRC) and its subsites.
- To identify proteins causally associated with CRC risk.
- To investigate the functional roles and drug predictabilities of identified proteins.
Main Methods:
- Proteome-wide and genome-wide association studies (GWAS) were conducted on a large Icelandic cohort.
- Two-sample Mendelian randomization (MR) and colocalization analyses identified protein-CRC associations.
- Proteins were further validated in the FinnGen study, with enrichment and drug prediction analyses performed.
Main Results:
- 31 proteins showed robust causal associations with CRC, with site-specific effects observed.
- CHDRL2 was identified as a common target for CRC and its subsites.
- IGF2R and ENPEP were specifically associated with colon cancer, and ASRGL1 with rectal cancer.
Conclusions:
- CHDRL2 is a promising common therapeutic target for colorectal cancer, colon cancer, and rectal cancer.
- IGF2R, ENPEP, and ASRGL1 represent site-specific therapeutic targets for colon and rectal cancers, respectively.
- The identified proteins offer potential avenues for targeted drug development in CRC treatment.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets